Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 mg » 5 mm (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 mg » 5 mm (Expand Search)
-
1541
-
1542
-
1543
-
1544
-
1545
-
1546
-
1547
-
1548
Changes in neural activity were decreased in animals pre-exposed to 5-HT and <i>mod-1</i> mutants when the worms switched their locomotive direction.
Published 2019“…<p>(A–F) the neural activity of the RID changes during the transition periods from backward to forward locomotion (A–C) and from forward to backward locomotion (D–F) in the mock (A: p = 1.5 × 10<sup>−5</sup>; D: p = 5.5 × 10<sup>−13</sup>), 5-HT exposed (B: p = 0.092; E: p = 0.79), and <i>mod-1</i> mutant (C: p = 0.081; F: p = 0.93) groups. …”
-
1549
<i>Ext1</i> mutant lungs exhibit a decrease in SHH-FGF10 signaling.
Published 2017“…<p>(A) qPCR analysis of key components of FGF signaling pathway in lungs from E14.5. …”
-
1550
-
1551
-
1552
-
1553
-
1554
-
1555
Transforming growth factor (TGF)-β1 induced a robust decrease in S-phase in non-cancer cell strains
Published 2011“…Representative histograms are presented illustrating cells that had a robust decrease in S-phase (NMuMG), modest decrease in S-phase (EpH4), and no decrease in S-phase (MDA-MB-436) as a result of TGF-βtreatment. …”
-
1556
-
1557
-
1558
List of Included studies.
Published 2025“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
1559
The search strategy in three databases.
Published 2025“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
1560
NIH score.
Published 2025“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”